丹参注射液对不稳定型心绞痛患者血清可溶性细胞间黏附分子 1的影响

目的： 探讨不稳定型心绞痛(UAP)患者血清中可溶性细胞间黏附分子 1(sICAM 1)和C 反应蛋白(CRP)的水平与正常人的差异，及其在丹参注射液治疗前后的变化。方法：将64例UAP患者随机分为对照组1(常规治疗组)31例及治疗组(丹参注射液治疗组)33例，对照组1采用常规治疗即吸氧，镇静，阿司匹林100 mg，qd；美托洛尔12.5～25 mg，每天2或3次。治疗组在常规治疗基础上，给予丹参注射液30 mL加5%葡萄糖注射液250 mL，静脉滴注，qd。两组疗程均为14 d。通过ELISA法检测治疗前后血清sICAM 1和CRP水平的变化，并与对照组2(正常对照组)22例对比分析。观察两组疗效。结果：UAP患者血清sICAM 1和CRP水平较对照组2明显升高(均为P＜0.01)，对照组1及治疗组治疗后sICAM 1及CRP水平较治疗前明显降低(均为P＜0.01)，且治疗组下降幅度显著较对照组1大(P＜0.05)。治疗组较对照组1临床疗效更显著(P＜0.05)，但心电图疗效差异无显著性(P＞0.05)。结论：CRP、sICAM 1可能参与了冠心病(CHD)的发病过程，血清sICAM 1的检测有助于临床病情分析，丹参注射液能显著降低UAP患者血清sICAM 1和CRP水平，与常规西药联合治疗冠心病疗效更好，从而降低冠状动脉事件的发生率。

Change of Serum sICAM-1 in UAP Patients Treated by Danshen Injection

Objective:To observe the change of soluble intercellular adhesion molecule-1 (sICAM-1), C-reactive protein (CRP) between healthy man and the patients with unstable angina pectoris (UAP), and the effect of danshen injection on the level of sICAM-1 and CRP in patients with UAP. Methods:Sixty-four suitable patients with UAP were randomized into two groups, the first control group -31 cases, treated routinely and the treatment group-33 cases treated by adding danshen injection to the former treatment. The serum levels of sICAM-1 and CRP of the patients with UAP were tested before and after the treatment, and were compared to the second control group (22 healthy man) by ELISA. The clinical effects were observed. Results:The serum levels of sICAM-1 and CRP in UAP patients were significantly higher than in the second control group (P<0.01). After treatment, the level of sICAM-1 and CRP in UAP patients were significantly lower than before (P<0.01). The effect in treatment group was significantly superior than in the first control group (P<0.05), however, ECG had no significant improvement (P>05). Conclusion:The level of sICAM-1 and CRP may be the risk factors of CHD and they may be used to predict prognosis. Danshen injection can lower the level of sICAM-1 and CRP.